Editorial standards

Every page is built from a claims ledger: each factual statement is entered as a discrete claim, matched to a primary source fetched on a recorded date, stored with the exact supporting language, and graded by evidence type (FDA label statement, human RCT, human study, animal finding, regulatory record, review, or derived arithmetic). Statements about tesamorelin's approval and safety rules come only from the current EGRIFTA SV and EGRIFTA WR labels (both effective 2026-07-29) and FDA records. Study findings name their species in the study table, and a human-trial chip is never placed on animal data. No physician or clinician has reviewed this site, and we do not claim medical review; what we claim is that every number resolves to its cited source, and the machine-readable ledger that proves it ships with the site.

Allowed sources: FDA (labels, Drugs@FDA, official FDA pages), DailyMed, PubMed-indexed peer-reviewed journals, ClinicalTrials.gov, and PubChem. Not allowed: clinic marketing pages, peptide vendors, wellness blogs, press releases, and secondary aggregators. Where the honest answer is an absence (no approval outside HIV-associated lipodystrophy, no carcinogenicity studies, no data over age 65), we cite the label or review that documents the absence and say so plainly.

Each page displays its published and last-updated dates. We re-review this compound's pages when any of the following changes: the EGRIFTA SV or WR label (new SPL version), FDA action on application BLA 022505, or publication of a randomized human trial that would change a conclusion. Scheduled re-checks include re-resolving every citation link. Material changes get a dated note on the affected page.

If we got something wrong, we want it gone. Use the corrections link in the site footer and include the page URL and the claim you dispute. Verified corrections are made on the page with a dated note; claims that fail re-verification are removed from the ledger and from every surface that rendered them. We treat a citation that does not support its claim as the most serious defect this site can have.

The '34 sources' figure is the length of the numbered references list rendered from the monograph citation manifest (17 peer-reviewed, 17 government, a census computed from the same array). The '14 studies / 12 human' figures are the row count and species-column count of the study-results table. The '1 approved use' figure is the count of indication entries rendered from the decision aid, each quoting the label. Trial statistics (VAT percentages, adverse-reaction rates, IGF-1 thresholds) are quoted from the FDA label or the cited paper and were not computed by us. Any internal count shown on this site must be recomputable by script from the page that displays it; if an array changes, the displayed number changes in the same update.